March 14, 2013
Mark Lundstrom Named By The Aspen Institute As 2013 Henry Crown Fellow

BioScale, Inc. a life science company that develops high-precision, sensitive protein analysis technology, today announced  that its CEO, Mark Lundstrom, was named  by the Aspen Institute as a member of the  2013 Class of Henry Crown Fellows. The Henry Crown Fellowship engages the next generation of leaders in the challenge of community-spirited leadership.

March 05, 2013
Presentation of Collaborative Research by the NCI, UCSF-Helen Diller Comprehensive Cancer Center and BioScale Researchers at the 2013 American Association of Cancer Research (AACR) Meeting

Four presentations examine analyses of pathways from in vitro and in vivo tumors, tumor cell lines and siRNA sequences using AMMP® Technology

BioScale, Inc. a life science company that develops high-precision, sensitive protein analysis technology, today announced that data from its internal research program and collaborations with the National Cancer Institute (NCI) Antibody & Protein Purification Unit and the Frank McCormick laboratory at UCSF Helen Diller Family Comprehensive Cancer Center were accepted for presentation and publication in the proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR).  The Conference will be held at the Walter E. Washington Convention Center in Washington, DC from April 6 - April 10, 2012. Details of the four poster presentations focusing on signal transduction pathway analysis, tumor fingerprinting, rapid assay development and cell line screening of siRNA sequences for viability and pathway disruption are presented below.

February 07, 2013
BioScale Participates in Seminar Series at University of California at San Francisco (UCSF) and Stanford University’s Canary Center

BioScale, Inc. a life science company that develops high-precision, sensitive protein analysis technology, recently participated in two seminars held at University of California at San Francisco (UCSF) and Stanford University’s Canary Center.  The research seminars entitled: “Novel Biomarker Approaches” featured presentations from studies done using novel technologies for lung and prostate cancers as well as pathway analysis used in targeted therapeutic development.  Dr.

January 11, 2013
BioScale Presents Data from Cytokine Assay Development Studies Using AMMP Assays at the 2013 SLAS Conference

 BioScale, Inc. a life science company that develops high-precision, sensitive protein analysis technology, presented findings from several completed research studies on cytokine analysis demonstrating the flexibility, rapid assay development and robust assay characteristics of its AMMP® assay technology during theAnnual Society of Laboratory Automation and Screening (SLAS) meeting, held in Orlando, FL, January 14 - 16, 2013.